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Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare inherited endocrine tumor
syndrome principally affecting parathyroid glands, neuroendocrine tissues of the
gastro-entero-pancreatic and thoracic tracts, and anterior pituitary, caused by germline
inactivatingmutations of theMEN1 tumor suppressor gene. Primary hyperparathyroidism
(PHPT) is usually the first clinical manifestation of the syndrome, normally manifesting
during the third decade of life. Cases of affected children and adolescents have been
described by the age of 5. Clinical characteristics and therapeutic management of
MEN1 in adolescents have been described mainly by case reports. Only two studies
on MEN1 patient series under the age of 22 years have recently been published.
Given the scarcity of data and the lack of a consistent number of targeted studies,
there are currently no specific guidelines available for children and adolescents with
MEN1; diagnostic and therapeutic management is, thus, usually the same as for
adult patients. Here, we report our experience with 19 adolescent MEN1 patients,
developing MEN1-associated PHPT before the age of 20. Fourteen of them, manifesting
hypercalcemic PHPT before the age of 20 underwent parathyroidectomy before the
age of 25 to control calcemia. Parathyroid surgery restored normal calcemia in all the
operated patients. No post-surgical nephrolithiasis has been reported after a mean of
12.0 ± 5.8 years of follow-up. Comparison between pre-surgical and post-surgical
values of bone mineral density (BMD) in 2 patients evidenced an improvement of bone
mass after parathyroid adenoma ablation. Two patients (14.28%) developed permanent
post-surgical hypoparathyroidism.
Keywords: Multiple Endocrine Neoplasia Type 1, primary hyperparathyroidism, parathyroid adenomas,
parathyroidectomy, MEN1 adolescent patients
INTRODUCTION
Primary hyperparathyroidism (PHPT), caused by hyperplasia and/or adenomas of the
parathyroids, is the most common (up to 100% after the age of 55 years) and, in the great
majority of cases, the first clinical manifestation in Multiple Endocrine Neoplasia Type 1 (MEN1),
a rare endocrine inherited multiple tumor syndrome caused by germline heterozygote inactivating
mutations of theMEN1 tumor suppressor gene.
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PHPT in MEN1 manifests principally between 20 and 30
years of age, often remaining asymptomatic for years before
being casually discovered during serum biochemical screening
in index cases or being recognized by yearly biochemical dosage
of parathyroid hormone (PTH) and serum calcium in MEN1
mutation carriers. Cases of PHPT developed during childhood
and adolescence have also been reported (1).
Since 1997, the application of the MEN1 genetic test in
members of mutated pedigrees has allowed the identification
of asymptomatic carriers and a constant screening program
for the early recognition of MEN1-associated biochemical signs
and tumors (2). This has permitted increasingly frequent
identification of PHPT cases during childhood and adolescence
and treatment at a younger age.
Parathyroid surgery is the treatment of choice for MEN1-
PHPT; surgical removal of abnormal gland/glands is the most
effective and rapid cure for restoring normal parathyroid activity
and quickly normalizing calcemia (3).
Available data about clinical characteristics and therapeutic
management of MEN1-PHPT during childhood and adolescence
are principally derived from very few single case reports.
Only two studies (4, 5) on series of children and adolescents
with MEN1 have recently been published. Both these studies
confirmed PHPT as the most common and first clinical
manifestation, also in young patients (58.3 and 73.8%,
respectively), being asymptomatic in the great majority of
cases (90.9 and 86%, respectively) and clinically diagnosed
during yearly PHPT surveillance for MEN1 patients and/or for
MEN1 gene mutation carriers.
To date, no specific guidelines are available about the
treatment of MEN1 and related PHPT in young individuals,
and both medical and surgical therapies are usually the same as
those applied to adults, according to the last international MEN1
guidelines (1). Currently, the right timing for surgery and the
best surgical approach to treat MEN1-PHPT during the first two
decades of life are still controversial.
In this paper, we describe our experience with MEN1
adolescent patients with PHPT, collected and followed-up
through the Regional Referral Center for Inherited Endocrine
Tumors of the Tuscany Region, at the “Azienda Ospedaliera-
Universitaria Careggi,” Florence, Italy.
METHODS
Patients
This study was approved by the Review Board of the “Area
Vasta Centro, Regione Toscana” at the “Azienda Ospedaliera-
Universitaria Careggi” (Rif. CEAVC OSS 16.234). All patients, or
legal tutors for individuals under the age of 18, gave informed
consent for data collection and analysis. All collected data were
made appropriately anonymous and each patient was identified
by a specific identification number; data were also analyzed as
aggregates. Patients were collected and clinically followed up at
the Ambulatory of the Regional Referral Center for Inherited
Endocrine Tumors of the Tuscany Region from 1991 to 2017.
A total of 30 patients (17 females and 13 males), diagnosed
with MEN1 before the age of 20, were collected in the database.
Genetic MEN1 diagnosis was made by Sanger’s sequencing
analysis of theMEN1 gene. The entire coding region (exons 2-10)
and splicing sites were screened in index cases. Target searching
for the pedigree-specific mutation was performed in relatives of
mutated patients.
Clinical diagnosis of MEN1 was made in the presence of at
least one sign and/or symptom of oneMEN1-associated tumor in
familial cases, and of at least two signs and/or symptoms of one of
the three principal MEN1-associated tumors in single cases (i.e.,
patient no. 20 presenting PHPT and insulinoma and patient no.
36 presenting PHPT and prolactinoma).
After MEN1 diagnosis (clinical or genetic), all patients were
directed into the specific routine screening program for MEN1
tumors (1), including annual dosage of PTH (elevated PTH is
considered over 7.6 pmol/l), total serum calcium (hypercalcemia
is defined with value over 10.1 mg/dl), and calcium ion for the
diagnosis of PHPT. Annual serum dosage of phosphorus was
also performed (value <2.5 mg/dl, associated with elevated PTH,
strengthens the diagnosis of PHPT).
Computed axial tomography (CAT) of kidneys were
performed approximately every 2 years for monitoring the
presence of renal calculi. Data about pre-operative dual X-ray
absorptiometry (DEXA) evaluations of lumbar spine, femoral
neck and total femur bone mineral density (BMD) were available
only for two patients.
Pre-operatory imaging screening, by echo-color Doppler
ultrasonography of the neck and cervical and mediastinal
scintigraphy by Tc-99m sestamibi, were performed in all operated
patients for the localization of parathyroids and the identification
of possible super-numerary and/or ectopic glands, respectively.
All operated patients were followed-up by a yearly surveillance
program for serum PTH and calcium to monitor post-surgical
persistence and recurrences, as well as clinical and biochemical
surveillance for MEN1 tumors (1). Post-surgical renal CAT
was performed, approximately every 2 years, to monitor
nephrolithiasis in all patients, with a mean of follow-up of 12.0
± 5.8 years (range 3–23 years).
Three different surgical approaches were applied to our
operated patients: (1) the resection of only the affected
parathyroids, up to three glands (partial parathyroidectomy;
PPTX), (2) the removal of three parathyroids and part of the
fourth gland, the one appearing non-enlarged or hyperplastic
(subtotal parathyroidectomy; STPTX), and (3) the complete
ablation of all parathyroids (total parathyroidectomy, TPTX)
with auto-transplantation of normal parathyroid tissue in the
non-dominant forearm.
Intra-operative dosage of PHT was performed during all
interventions to monitor PTH levels, to confirm the ablation of
all affected glands.
RESULTS
Our database included a total of 30 patients diagnosed with
MEN1 before the age of 20 (mean age at first MEN1 diagnosis
11.87 ± 4.92 years; range 0–20 years), all, but one, with a
positiveMEN1 genetic test. Nineteen were first diagnosed by the
genetic test, while 11 had a MEN1 clinical diagnosis before the
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performance of the genetic test (individuals collected before the
development ofMEN1 testing).
Annual biochemical evaluation of PTH, total serum calcium
and calcium ion, starting by the time of MEN1 diagnosis, allowed
the recognition of PHPT at its onset.
Ten of 30 subjects (33.33%), aged <20 years at the time of
this study, have not shown any sign or symptom of MEN1; they
were diagnosed with MEN1 only by the genetic test. One female
patient developed a prolactinoma at the age of 13, but she had
not manifested any sign of PHPT at the time of this study (age of
24 years). They are all still under clinical surveillance for MEN1
tumors (1).
Nineteen individuals (13 females and 6 males; 19/30; 63.33%)
showed elevated serum level (over 7.6 pmol/L; normal range
1.3–7.6 pmol/L) of PTH before the age of 20 (mean age of first
recognition of elevated PTH serum level 16.32 ± 2.15 years;
range 12–19 years). They included 2 MEN1 single cases (1 with
an identified MEN1 gene mutation, and 1 negative to MEN1
sequencing analysis but clinically diagnosed with MEN1), and
17 MEN1 familial cases from 13 different pedigrees (16 with
an identified MEN1 gene mutation and 1 with two different
MEN1 mutations, both located on the same gene allele). Three
of 19 patients were referred to our Endocrine Referral Center
as affected index cases [2 MEN1 single cases (1 with a negative
MEN1 genetic test but clinically diagnosed as MEN1) and 1
MEN1 familial case (with both genetic and clinical MEN1
diagnosis)]. The other 16 individuals were relatives of MEN1
index cases, and they were diagnosed by the clinical recognition
of MEN1 signs and symptoms as members of affected MEN1
families and/or by the genetic test (in families with a previously
identifiedMEN1 gene mutation).
Five of these 19 patients (26.32%) (mean age at first
recognition of elevated PTH serum level 16.20± 2.63 years; range
12–19 years), were still normocalcemic and asymptomatic at the
time of this study and did not undergo parathyroid surgery. Main
individual clinical characteristics of non-operated patients are
reported in Table 1.
The other fourteen PHPT patients (14/19; 73.68%) were
diagnosed with PHPT (mean age at PHPT clinical diagnosis 16.36
± 1.95 years; range 13–19 years), manifested hypercalcemia (all
of them >11 mg/dL of total serum calcium) and underwent
parathyroid surgery. Twelve (63.16%) presented hypercalcemia
before the age of 20 and were operated under the same age
(mean age at surgical intervention 17.08 ± 2.18 years; range 13–
20 years). The other two patients were operated, respectively, at
the ages of 22 and 25 years. For the first one (case 3, Table 2),
the decision for surgery was delayed up to the manifestation of
hypercalcemia at the age of 22. The second one (case 9, Table 2)
was treated (after developing the first sign of hypercalcemia at the
age of 21) for about 3 years with cinacalcet, before the decision for
surgery because of a severe osteoporosis at the age of 25.
The main individual clinical characteristics at the time
of parathyroid surgery of our operated MEN1 patients are
summarized in Table 2.
Pre-operatory imaging screenings allowed us to recognize
ectopic parathyroids in two patients (2/14; 14.29%) (cases 29
and 36 in Tables 2, 3). In particular, scintigraphy permitted us TA
B
L
E
1
|
M
a
in
in
d
iv
id
u
a
lc
lin
ic
a
lc
h
a
ra
c
te
ris
tic
s
o
f
M
E
N
1
in
d
iv
id
u
a
lw
ith
n
o
rm
o
c
a
lc
e
m
ic
e
le
va
te
d
P
T
H
le
ve
l,
w
h
o
d
id
n
o
t
u
n
d
e
rg
o
P
T
X
.
P
a
ti
e
n
t’
s
n
u
m
e
ri
c
c
o
d
e
G
e
n
d
e
r
M
E
N
1
s
in
g
le
c
a
s
e
(S
)
o
r
fa
m
il
ia
l
fo
rm
(F
)
A
g
e
a
t
M
E
N
1
g
e
n
e
ti
c
d
ia
g
n
o
s
is
A
g
e
a
t
M
E
N
1
c
li
n
ic
a
l
d
ia
g
n
o
s
is
F
ir
s
t
M
E
N
1
c
li
n
ic
a
l
m
a
n
if
e
s
ta
ti
o
n
A
g
e
a
t
P
H
P
T
c
li
n
ic
a
l
d
ia
g
n
o
s
is
S
y
m
p
to
m
a
ti
c
(S
)
o
r
a
s
y
m
p
to
m
a
ti
c
(A
)
P
H
P
T
N
o
rm
o
c
a
lc
e
m
ia
(N
)
o
r
h
y
p
e
rc
a
lc
e
m
ia
(H
)
O
s
te
o
p
e
n
ia
o
r
o
s
te
o
p
o
ro
s
is
N
e
p
h
ro
li
th
ia
s
is
O
th
e
r
M
E
N
1
n
e
u
ro
e
n
d
o
c
ri
n
e
tu
m
o
rs
a
t
th
e
ti
m
e
o
f
P
H
P
T
d
ia
g
n
o
s
is
N
o
te
s
4
2
M
F
1
6
1
5
P
H
P
T
/P
R
L
o
m
a
1
5
A
N
n
.a
.
N
O
P
R
L
o
m
a
4
3
F
F
1
0
1
6
P
H
P
T
1
6
A
N
n
.a
.
N
O
N
O
P
a
tie
n
t
re
fu
se
d
to
u
n
d
e
rg
o
P
T
X
a
n
d
sh
e
h
a
s
b
e
e
n
tr
e
a
te
d
w
ith
c
in
a
c
a
lc
e
t
si
n
c
e
2
0
0
7
4
4
M
F
7
1
9
P
H
P
T
/P
R
L
o
m
a
1
9
A
N
n
.a
.
N
O
P
R
L
o
m
a
4
5
F
F
9
1
9
P
H
P
T
1
9
A
N
n
.a
.
N
O
N
O
4
6
F
F
1
2
1
2
P
H
P
T
1
2
A
N
n
.a
.
N
O
N
O
P
H
P
T,
p
ri
m
a
ry
h
yp
e
rp
a
ra
th
yr
o
id
is
m
;
P
T
H
,
p
a
ra
th
yr
o
id
h
o
rm
o
n
e
;
P
T
X
,
p
a
ra
th
yr
o
id
e
c
to
m
y;
P
R
L
o
m
a
,
p
ro
la
c
ti
n
o
m
a
;
n
.a
.,
n
o
n
-a
va
ila
b
le
.
P
a
ti
e
n
ts
4
3
a
n
d
4
4
b
e
lo
n
g
to
o
n
e
fa
m
ily
(b
ro
th
e
r
a
n
d
s
is
te
r)
a
n
d
th
e
y
a
re
a
ls
o
b
ro
th
e
rs
o
f
p
a
ti
e
n
t
9
(T
a
b
le
2
).
Frontiers in Endocrinology | www.frontiersin.org 3 October 2018 | Volume 9 | Article 597
Marini et al. Parathyroidectomy in Adolescents With MEN1
T
A
B
L
E
2
|
M
a
in
in
d
iv
id
u
a
lc
lin
ic
a
lc
h
a
ra
c
te
ris
tic
s
o
f
P
H
P
T-
a
ff
e
c
te
d
M
E
N
1
p
a
tie
n
ts
a
t
th
e
tim
e
o
f
p
a
ra
th
yr
o
id
su
rg
e
ry
.
P
a
ti
e
n
t’
s
n
u
m
e
ri
c
c
o
d
e
G
e
n
d
e
r
M
E
N
1
s
in
g
le
c
a
s
e
(S
)
o
r
fa
m
il
ia
l
fo
rm
(F
)
A
g
e
a
t
M
E
N
1
g
e
n
e
ti
c
d
ia
g
n
o
s
is
A
g
e
a
t
M
E
N
1
c
li
n
ic
a
l
d
ia
g
n
o
s
is
F
ir
s
t
M
E
N
1
c
li
n
ic
a
l
m
a
n
if
e
s
ta
ti
o
n
A
g
e
a
t
P
H
P
T
c
li
n
ic
a
l
d
ia
g
n
o
s
is
S
y
m
p
to
m
a
ti
c
(S
)
o
r
a
s
y
m
p
to
m
a
ti
c
(A
)
P
H
P
T
N
o
rm
o
c
a
lc
e
m
ia
(N
)
o
r
h
y
p
e
rc
a
lc
e
m
ia
(H
)
O
s
te
o
p
e
n
ia
o
r
o
s
te
o
p
o
ro
s
is
N
e
p
h
ro
li
th
ia
s
is
O
th
e
r
M
E
N
1
n
e
u
ro
e
n
d
o
c
ri
n
e
tu
m
o
rs
a
t
th
e
ti
m
e
o
f
P
T
X
N
o
te
s
1
F
F
2
0
1
5
P
R
L
o
m
a
1
5
S
H
O
st
e
o
p
e
n
ia
(lu
m
b
a
r
sp
in
e
a
n
d
fe
m
u
r)
N
O
P
R
L
o
m
a
3
M
F
1
3
1
5
P
H
P
T
1
5
A
H
n
.a
.
N
O
N
O
9
M
F
1
3
1
2
P
R
L
o
m
a
1
6
S
H
S
e
ve
re
o
st
e
o
p
o
ro
si
s
(lu
m
b
a
r
sp
in
e
a
n
d
fe
m
u
r)
N
O
P
R
L
o
m
a
F
ra
g
ili
ty
fr
a
c
tu
re
o
f
th
e
d
is
ta
l
e
p
ip
h
ys
is
o
f
ra
d
ia
lb
o
n
e
V
ita
m
in
D
d
e
fic
ie
n
c
y
U
n
re
se
c
ta
b
le
m
a
c
ro
P
R
L
o
m
a
p
o
o
rl
y
re
sp
o
n
si
ve
to
p
h
a
rm
a
c
o
lo
g
ic
a
lt
h
e
ra
p
y
S
e
ve
re
d
e
fic
ie
n
c
y
o
f
te
st
o
st
e
ro
n
e
(p
h
a
rm
a
c
o
lo
g
ic
a
l
su
b
st
itu
tiv
e
th
e
ra
p
y)
1
0
*
F
F
1
9
1
7
In
su
lin
o
m
a
1
8
A
H
n
.a
.
N
O
In
su
lin
o
m
a
S
u
rg
ic
a
lr
e
se
c
tio
n
o
f
in
su
lin
o
m
a
w
a
s
p
e
rf
o
rm
e
d
1
ye
a
r
b
e
fo
re
P
T
X
1
2
F
F
1
9
1
7
P
H
P
T
(k
id
n
e
y
c
o
lic
a
n
d
st
o
n
e
s)
1
8
S
H
n
.a
.
Y
E
S
N
O
1
6
F
F
2
9
1
9
P
R
L
o
m
a
1
9
A
H
n
.a
.
N
O
P
R
L
o
m
a
1
8
F
F
1
3
1
4
P
H
P
T
(k
id
n
e
y
c
o
lic
)
1
4
S
H
n
.a
.
Y
E
S
N
O
2
0
*
F
S
2
8
2
0
P
H
P
T
1
5
S
H
n
.a
.
Y
E
S
In
su
lin
o
m
a
In
su
lin
o
m
a
w
a
s
d
e
te
c
te
d
a
n
d
su
rg
ic
a
lly
re
se
c
te
d
b
e
tw
e
e
n
th
e
fir
st
a
n
d
th
e
se
c
o
n
d
P
T
X
2
2
F
F
1
9
1
8
P
H
P
T
(k
id
n
e
y
st
o
n
e
s)
1
8
S
H
n
.a
.
Y
E
S
N
O
2
6
M
F
2
5
1
8
P
H
P
T
1
8
A
H
n
.a
.
N
O
P
R
L
o
m
a
,
in
su
lin
o
m
a
In
su
lin
o
m
a
w
a
s
su
rg
ic
a
lly
re
se
c
te
d
th
e
sa
m
e
ye
a
r
o
f
P
T
X
2
7
F
F
8
1
4
P
H
P
T
1
4
A
H
n
.a
.
N
O
N
O
2
9
M
F
1
1
1
4
P
R
L
o
m
a
1
7
A
H
n
.a
.
N
O
P
R
L
o
m
a
3
6
*
F
S
N
e
g
a
tiv
e
M
E
N
1
se
q
u
e
n
c
in
g
te
st
1
3
P
R
L
o
m
a
1
3
A
H
n
.a
.
N
O
P
R
L
o
m
a
3
8
F
F
3
4
1
9
P
H
P
T
1
9
A
H
n
.a
.
N
O
N
O
To
ta
lt
h
yr
o
id
e
c
to
m
y
fo
r
H
u
rt
le
c
e
ll
c
a
rc
in
o
m
a
a
t
th
e
tim
e
o
f
fir
st
P
T
X
P
H
P
T,
p
ri
m
a
ry
h
yp
e
rp
a
ra
th
yr
o
id
is
m
;
P
T
H
,
p
a
ra
th
yr
o
id
h
o
rm
o
n
e
;
P
T
X
,
p
a
ra
th
yr
o
id
e
c
to
m
y;
P
R
L
o
m
a
,
p
ro
la
c
ti
n
o
m
a
;
n
.a
.,
n
o
n
-a
va
ila
b
le
.
P
a
ti
e
n
ts
in
d
ic
a
te
d
w
it
h
th
e
*
w
e
re
re
fe
rr
e
d
to
o
u
r
C
e
n
te
r
a
s
M
E
N
1
a
ff
e
c
te
d
in
d
e
x
c
a
s
e
s
.
P
a
ti
e
n
ts
1
0
a
n
d
1
2
b
e
lo
n
g
to
o
n
e
fa
m
ily
(t
w
o
s
is
te
rs
);
p
a
ti
e
n
ts
2
6
a
n
d
2
7
to
o
n
e
fa
m
ily
(2
6
is
u
n
c
le
o
f
2
7
).
P
a
ti
e
n
t
9
is
b
ro
th
e
r
o
f
p
a
ti
e
n
ts
4
3
a
n
d
4
4
(T
a
b
le
1
).
Frontiers in Endocrinology | www.frontiersin.org 4 October 2018 | Volume 9 | Article 597
Marini et al. Parathyroidectomy in Adolescents With MEN1
T
A
B
L
E
3
|
M
a
in
c
h
a
ra
c
te
ris
tic
s
o
f
p
a
ra
th
yr
o
id
su
rg
e
ry
in
o
u
r
M
E
N
1
a
d
o
le
sc
e
n
t
p
a
tie
n
ts
(u
p
to
2
0
ye
a
rs
o
f
a
g
e
a
t
th
e
tim
e
o
f
P
H
P
T
c
lin
ic
a
ld
ia
g
n
o
si
s)
.
P
a
ti
e
n
t’
s
n
u
m
e
ri
c
c
o
d
e
M
E
N
1
g
e
n
e
m
u
ta
ti
o
n
A
g
e
a
t
P
H
P
T
c
li
n
ic
a
l
d
ia
g
n
o
s
is
A
g
e
a
t
fi
rs
t
P
T
X
S
u
rg
ic
a
l
in
te
rv
e
n
ti
o
n
ty
p
e
N
o
rm
a
l
p
a
ra
th
y
ro
id
ti
s
s
u
e
a
u
to
-r
e
-i
m
p
la
n
ta
ti
o
n
d
u
ri
n
g
fi
rs
t
P
T
X
P
H
P
T
p
e
rs
is
te
n
c
e
a
ft
e
r
th
e
fi
rs
t
P
T
X
P
H
P
T
re
c
u
rr
e
n
c
e
a
ft
e
r
th
e
fi
rs
t
P
T
X
S
e
c
o
n
d
P
T
X
(r
e
-
in
te
rv
e
n
ti
o
n
)
A
g
e
a
t
s
e
c
o
n
d
P
T
X
N
o
rm
a
l
p
a
ra
th
y
ro
id
ti
s
s
u
e
a
u
to
-r
e
-i
m
p
la
n
ta
ti
o
n
d
u
ri
n
g
s
e
c
o
n
d
P
T
X
P
o
s
t-
s
u
rg
ic
a
l
h
y
p
o
p
a
ra
th
y
ro
id
is
m
1
M
is
se
n
se
G
ly
1
6
3
A
rg
,
e
xo
n
3
1
5
2
0
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
Y
e
s
3
N
o
n
se
n
se
G
ln
5
0
8
S
to
p
,
e
xo
n
1
0
1
5
2
2
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
Y
e
s
9
S
p
lic
in
g
g
.8
9
3
+
1
(G
>
A
),
in
tr
o
n
4
1
6
2
5
S
T
P
T
X
(P
H
P
T
w
a
s
p
re
vi
o
u
sl
y
tr
e
a
te
d
w
ith
c
in
a
c
a
lc
e
t
fo
r
3
ye
a
rs
b
e
fo
re
su
rg
e
ry
)
N
o
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
1
0
*
N
o
n
se
n
se
A
rg
4
6
0
S
to
p
,
e
xo
n
1
0
1
8
1
8
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
1
2
N
o
n
se
n
se
A
rg
4
6
0
S
to
p
,
e
xo
n
1
0
1
8
1
8
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
1
6
F
ra
m
e
sh
ift
g
.1
3
6
4
d
e
lC
,
e
xo
n
9
1
9
1
9
T
P
T
X
Y
e
s
N
o
Y
e
s
T
P
T
X
(fo
re
a
rm
re
im
p
la
n
t)
3
0
n
o
N
o
1
8
M
is
se
n
se
V
a
l1
9
6
G
ly
,
e
xo
n
3
1
4
1
5
P
P
T
X
(1
g
la
n
d
)
N
o
N
o
Y
e
s
P
P
T
X
(1
g
la
n
d
)
1
9
n
.a
.
N
o
2
0
*
M
is
se
n
se
H
is
1
8
1
A
sp
,
e
xo
n
3
1
5
1
5
P
P
T
X
(1
g
la
n
d
)
N
o
N
o
Y
e
s
T
P
T
X
2
9
ye
s
N
o
2
2
M
is
se
n
se
Tr
p
2
2
0
A
rg
,
e
xo
n
4
1
8
1
8
P
P
T
X
(2
g
la
n
d
s)
N
o
Y
e
s
N
o
P
P
T
X
2
1
n
o
N
o
2
6
F
ra
m
e
sh
ift
g
.3
5
9
d
e
l(G
T
C
T
),
e
xo
n
2
1
8
1
9
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
2
7
F
ra
m
e
sh
ift
g
.3
5
9
d
e
l(G
T
C
T
),
e
xo
n
2
1
4
1
4
T
P
T
X
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
2
9
D
o
u
b
le
m
u
ta
tio
n
o
n
th
e
sa
m
e
M
E
N
1
a
lle
le
:
M
is
se
n
se
L
e
u
2
4
9
P
ro
,
e
xo
n
4
;
F
ra
m
e
sh
ift
g
.1
1
8
1
d
e
lC
,
e
xo
n
8
1
7
1
7
P
P
T
X
(1
e
c
to
p
ic
g
la
n
d
)
N
o
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
3
6
*
N
e
g
a
tiv
e
M
E
N
1
se
q
u
e
n
c
in
g
te
st
1
3
1
3
T
P
T
X
(in
c
lu
d
e
d
2
a
d
d
iti
o
n
a
le
c
to
p
ic
g
la
n
d
s)
Y
e
s
N
o
N
o
N
o
n
.a
.
n
.a
.
N
o
3
8
F
ra
m
e
sh
ift
g
.1
6
5
6
in
sC
,
e
xo
n
1
0
1
9
1
9
S
T
P
T
X
N
o
N
o
Y
e
s
T
P
T
X
2
4
.
n
o
N
o
P
H
P
T,
p
ri
m
a
ry
h
yp
e
rp
a
ra
th
yr
o
id
is
m
;
P
T
X
,
p
a
ra
th
yr
o
id
e
c
to
m
y;
P
P
T
X
,
p
a
rt
ia
lp
a
ra
th
yr
o
id
e
c
to
m
y;
S
T
P
T
X
,
s
u
b
to
ta
lp
a
ra
th
yr
o
id
e
c
to
m
y;
T
P
T
X
,
to
ta
lp
a
ra
th
yr
o
id
e
c
to
m
y;
n
.a
.,
n
o
n
-a
p
p
lic
a
b
le
.
P
a
ti
e
n
ts
in
d
ic
a
te
d
w
it
h
th
e
*
w
e
re
re
fe
rr
e
d
to
o
u
r
C
e
n
te
r
a
s
M
E
N
1
a
ff
e
c
te
d
in
d
e
x
c
a
s
e
s
.
P
a
ti
e
n
ts
1
0
a
n
d
1
2
b
e
lo
n
g
to
o
n
e
fa
m
ily
(t
w
o
s
is
te
rs
);
p
a
ti
e
n
ts
2
6
a
n
d
2
7
to
o
n
e
fa
m
ily
(2
6
is
u
n
c
le
o
f
2
7
).
Frontiers in Endocrinology | www.frontiersin.org 5 October 2018 | Volume 9 | Article 597
Marini et al. Parathyroidectomy in Adolescents With MEN1
to identify an ectopic adenomatous gland in the mediastinum
aorto-pulmonary window of a patient 29 (Tables 2, 3).
The 14 operated patients presented a mean gap between
PTHP clinical diagnosis and surgery of 1.57 ± 2.95 years (range
0–9 years). Ten/fourteen (71.43%) underwent PTX the same
year as PHPT clinical diagnosis (0-year gap). At the time of
parathyroid surgery, eight hypercalcemic patients (8/14; 57.14%)
were still asymptomatic for PHPT, while six (6/14; 42.86%)
also manifested PHPT-related symptoms (four with kidney
stones, one osteopenia, and one severe osteoporosis with fragility
fracture of the distal epiphysis of radial bone). No correlation was
reported between the presence of hypercalcemia and/or value of
elevated calcium level and the manifestation of a symptomatic
PHPT, both in terms of nephrolithiasis and renal colic and bone
mass reduction.
Interestingly, six patients presented an active prolactinoma at
the time of PTX. One patient affected by insulinoma underwent
pancreatic surgery a year before PTX (case 10); another patient
was detected with an insulinoma and underwent pancreatic
resection between the first PTX and the re-intervention (case 20)
(Table 2).
TPTX was the most commonly performed intervention (8
cases; 57.14%) in all cases in association with normal parathyroid
tissue autograft (8–10 pieces of about 1 mm3 in volume of
the parathyroid gland appearing as non-adenomatous) in the
brachio-radial muscle of the non-dominant forearm, followed by
PPTX (4 cases; 28.57%) and STPTX (2 cases; 14.29%).
Five patients (35.71%) underwent a second PTX (mean age of
7.40 ± 4.32 years after the first surgical intervention; range 3–14
years), one for PHPT persistence (3 years after the first PPTX)
and four for recurrences (mean age of 8.50 ± 4.15 years after the
first surgical intervention; range 4–14 years). One re-intervention
was TPTX secondary to a precedent PPTX (20%), one was a
TPTX secondary to a precedent STPTX (20%), two were PPTX
secondary to a precedent PPTX (40%), and one was a TPTX to
totally remove adenoma recurrence at the forearm re-implant,
subsequent to a precedent TPTX (20%).
Two patients (14.29%) developed post-surgical permanent
hypoparathyroidism, both after TPTX (25% of performed
TPTX).
Main characteristics of parathyroid surgery in our 14 MEN1
operated adolescents are summarized in Table 3.
No patients developed nephrolithiasis during post-surgical
follow-up; the four patients with pre-operatory renal calculi
manifest no post-operatory variation in calculi number and/or
size.
Available data regarding pre- and post-operatory DEXA
measurement of BMD values at lumbar spine, femoral neck and
total femur are resumed in Table 4.
No association has been found between type and localization
of MEN1 mutations and PHPT clinical presentation and/or
response to surgery.
DISCUSSION
Parathyroid surgery represents the most effective therapy for
PHPT in MEN1 patients, granting the rapid restoration of both
normal PTH secretion and serum calcium level. A recent study by
Goswami et al. (6) evidenced that the cure of PHPT, in adults with
MEN1, significantly improved the health-related quality of life
regarding fatigue, depression, anxiety, and social life, suggesting
that parathyroid surgery should be prioritized in these patients.
Currently, the choice of the correct timing and the most decisive
type of PTX in MEN1 is still debated, both for adults and, even
more, for children and adolescents.
In general, studies on the clinical features of pediatric and
adolescent PHPT, both sporadic and inherited non-syndromic
or syndromic forms, are very limited, and comparisons between
series of Caucasian young and adult patients are still lacking.
A very recent study has compared 59 pediatric Chinese PHPT
patients (only 2 of them bearing a germline MEN1 mutation)
with 118 adult Chinese PHPT patients (7). The study has
demonstrated that pediatric PHPT can be successfully treated by
PTX like adults.
Two recent studies analyzed series of adolescent patients with
MEN1 (4, 5). The study of Goudet (5) reported that 60.7%
of their PHPT young patients (under the age of 21 years)
underwent parathyroid surgery; 67.57% were operated by a
PPTX/less than subtotal parathyroidectomy of only the affected
glands and 32.43% by a STPTX; no TPTX was performed in
their patients. Post-surgical results, in restoring normal calcemia,
inducing transitory and/or permanent hypocalcemia, and rate
of persistence and recurrences, were comparable with data
published regarding MEN1 adult patients (8–10). Vannucci et al.
(4) did not report any data about parathyroid surgery in their
series.
Neither guidelines nor surgeon consensus statements are
available at the moment regarding when and how PTX should
be performed in children and adolescents with MEN1-related
PHPT. Targeted studies to evaluate the effects of early PTX in
adolescents withMEN1-PHPT, both as positive clinical outcomes
and improvement of general quality of life, are surely required.
Persistent excess of PTH is responsible for increased bone
resorption and reduction of calcium deposition on bone tissue,
leading to a pathological loss of cortical and trabecular bone and
early osteopenia/osteoporosis with risk of fragility fractures both
in sporadic PHPT (11) andMEN1-related PHPT (12, 13).MEN1-
associated PHPT, which develops in young adults and also in
children and adolescents, can also severely alter the establishment
of bone mass peak and be responsible for a higher risk of severe
osteoporosis and fragility fractures (12, 13). Excessive PTH-
dependent bone loss is reversible; restoration of normal PTH
level is fundamental to block abnormal bone resorption and
recover healthy BMD and bone mass. Early surgery is the most
effective way to preserve bone mass in patients with MEN1-
PHPT (12, 14).
Thus, the decision for PTX timing and surgical approach in
MEN1 adolescents has to take into account the ratio between
benefits (in terms of clinical outcomes and general health-
related quality of life) and the risk of post-surgical complications
(i.e., permanent hypoparathyroidism in extensive surgery such
as STPTX and TPTX, or recurring laryngeal nerve damages
subsequent to neck re-operation after PPTX), and should be
driven on the basis of patient personal clinical characteristics (i.e.,
hypercalcemia, BMD value, kidney functionality and presence of
recurrent renal calculi, presence of other neuroendocrine tumors
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and related hormone-syndrome). Some clinical characteristics
may to lead a decision, both for adult and young patients, for
surgical intervention: (1) hypercalcaemia [to treat symptoms
(kidney stones, reduced bone calcium apposition, nausea,
anxiety, fatigue, lethargy, depression, confusion, anorexia,
vomiting, constipation, etc.) and to prevent consequences
of a prolonged untreated hypercalcaemia, such as kidney
insufficiency, osteoporosis, fragility fractures, neuromuscular
affections and cardiovascular morbidity], (2) symptomatic PHPT
(i.e., nephrolithiasis and/or osteopenia/osteoporosis; ablation
of tumors demonstrated to prevent future incidence of renal
calculi and to rapidly restore BMD value), (3) presence
of an active gastrinoma [i.e., elevated serum calcium level
increases gastrin secretion of gastrinoma, exacerbating Zollinger-
Ellison syndrome (ZES) and increasing the risk of peptic
ulcers] (15). The presence of an active insulinoma is an
absolute indication to postpone PTX until after curing the
hypoglycemia.
Interventions performed by experienced surgeons, within
multidisciplinary referral centers for inherited endocrine tumors
(in which a relatively high number of MEN1 cases are
operated every year), surely grant better therapeutic results and
positive post-surgical outcomes, both in terms of reduction of
complications and decrease of rate of persistence/recurrences.
Indication for parathyroid surgery for all our operated
patients was the presence of elevated PTH (over 7.6 pmol/L)
associated with hypercalcemia over the value of 11 mg/dL of
total serum calcium, both for symptomatic and asymptomatic
PHPT.
A suggested workup for the management of PHPT in MEN1
patients, including children and adolescents, is represented in
Figure 1.
Given the genetic predisposition in MEN1 mutated
individuals of every parathyroid cell to lose the second
wild type copy of the MEN1 gene and to randomly develop
multiple hyperplasia/adenoma (affecting, asynchronously, and
asymmetrically, all four glands during the patient’s lifetime), and
because of the common (up to 30%) presence of supernumerary
and/or ectopic parathyroids (16), all our patients were followed-
up by a yearly surveillance program for serum PTH and calcium
to monitor post-surgical persistence and recurrences. In our
young patients, surgical intervention restored normal values of
PTH and serum calcium (both as calcium ion and total serum
calcium).
Only one case of PHPT persistence was reported (after a
PPTX) to require a second PPTX 3 years after the first surgery.
Total rate of PHPT persistence and recurrences (5/14; 35.71%)
in our series is comparable to that reported in literature for
MEN1 patients (17). In our series, PPTX presented a high rate
of persistence (1/4; 25%) and recurrence (2/4; 50%), while TPTX
showed recurrence in only one case (1/8; 12.5%). We reported
two cases of permanent hypoparathyroidism, both after TPTX.
Our data indicate that the TPTX approach grants a longer
recurrent PHPT-free period, and a lower risk of re-intervention
(which most of the time is performed at the transplantation site
in the forearm and not at the neck). The risk of permanent
hypoparathyroidism is higher with TPTX, but it could be
mitigated over the years.
Pre-operatory and a post-operatory DEXA measurements of
BMD were available only for two individuals. One of them,
presenting pre-operatory hypercalcemia, lumbar spine T-score
−1.3 and Z-score −1.0, femoral neck T and Z-scores −1.8,
total femur T and Z-scores −1.4, showed to have recovered a
normal bone mass, as assessed by a lumbar and femoral DEXA
FIGURE 1 | Proposed PHPT workup in MEN1 patients.
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evaluation 4 years after surgery (lumbar spine T-score −0.4,
Z-score −0.3; femoral neck T and Z-scores −0.6; total femur
T and Z-scores −0.5). The other one, showing a pre-operative
borderline normocalcemia (controlled by cinacalcet) but a severe
osteoporosis (lumbar spine T and Z-scores−4.4; femoral neck T
and Z-scores−2.7; total femoral T and Z-scores−2.5) associated
with a fragility fracture, underwent a STPTX and did notmanifest
any PHPT persistence or recurrence up to 4 years after surgery.
However, he showed the persistence of a severe osteoporosis
(in presence of a post-operative normocalcemic status and a
correct PTH level) at two (lumbar spine T and Z-scores −3.9;
femoral neck T-score−2.4 and Z-score−2.3; total femoral T and
Z-scores −2.1) and three (lumbar spine T and Z-scores −3.5;
femoral neck T-score −2.4 and Z-score −2.3; total femoral T
and Z-scores −2.1) years after parathyroid surgery. These data
suggested that the severely reduced BMD in this very young
MEN1 patient was, presumably, not due to PHPT only. Indeed,
this young male presented, by the age of 12, an active non-
resectable macroprolactinoma poorly responsive to treatment
with high dosage of cabergoline, inducing severe deficiency of
testosterone and being, presumably, a major cause of the highly
reduced bone mass.
Several MEN1 mutations in our patients neither influenced
the clinical PHPT phenotype nor had any role in directing the
choice of individual PTX, both in terms of timing and type of
intervention. Rate of PHPT persistence and recurrences were
demonstrated to be dependent only on the type of parathyroid
surgery and not on the specificMEN1 gene mutation.
Our results confirmed PTX as the optimal treatment of
PHPT, presenting, in case of hypercalcemia > 11mg/dl, a good
benefit/risk balance, even in adolescents. Even if early PTX may
predispose young patients to earlier persistence/recurrences of
PHPT and the need of reoperation, a delay in surgical removal
of parathyroid tumors may worsen clinical consequences of long-
term hypercalcemia.
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